Thomas Gad - Jan 17, 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Founder, President, Interim Chief Executive Officer and Head of Business Development & Strategy, Director
Signature
/s/ Thomas Gad
Stock symbol
YMAB
Transactions as of
Jan 17, 2023
Transactions value $
$0
Form type
4
Date filed
1/19/2023, 03:42 PM
Previous filing
May 19, 2022
Next filing
Nov 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +40.5K +81% $0.00 90.5K Jan 17, 2023 Direct F1
holding YMAB Common Stock 565K Jan 17, 2023 By GAD Enterprises LLC F2
holding YMAB Common Stock 60K Jan 17, 2023 By Children F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +243K $0.00 243K Jan 17, 2023 Common Stock 243K $4.70 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 40,500 restricted stock units ("RSUs") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2024, January 17, 2025 and January 17, 2026 subject to the continuing employment of the Reporting Person on each vesting date.
F2 Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
F3 Represents shares owned by Reporting Person's children who are deemed to share Reporting Person's household.
F4 Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F5 The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 17, 2024, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Remarks:

Founder, President, Interim Chief Executive Officer and Head of Business Development & Strategy